Deals this week: Xiangxue Pharmaceutical, Auris Medical Holding, Enzymatica

16 February 2017 (Last Updated February 16th, 2017 18:30)

Xiangxue Pharmaceutical intends to raise up to ¥1.2bn ($188.47m) in a public offering of bonds.

Xiangxue Pharmaceutical intends to raise up to ¥1.2bn ($188.47m) in a public offering of bonds.

Based in China, the company produces and distributes patented medicines.

Swiss-based clinical-stage biopharmaceutical company Auris Medical Holding intends to raise $10m in gross proceeds from public offering of ten million units, each comprising one common share and one warrant at a price of $1 a unit.

The warrant holders will be entitled to purchase 0.7 of a common share for five years, at a price of $1.2 a share.

Underwriters are given a 30-day option to additionally purchase up to 1.5 million units to cover over-allotments, if any.

The net proceeds from the offering are intended to be used for working capital and general corporate purposes.

Swedish biotechnology company Enzymatica has signed an exclusive sales, marketing and distribution agreement with German pharmaceutical company STADA Arzneimittel for the former’s common cold product ColdZyme in Germany.

"Xiangxue Pharmaceutical intends to raise up to ¥1.2bn ($188.47m) in a public offering of bonds."

US-based biopharmaceutical company Xoma has announced the pricing for its registered direct offering of 1.2 million shares of its common stock and 5,003 shares of convertible preferred stock to be $4.03 a share and $4,030 a share respectively.

The offering will raise $25m in gross proceeds for the company and will be subscribed to by Biotechnology Value Fund and certain of its affiliates.

The proceeds are intended to be used for general corporate purposes.

Inovio Pharmaceuticals has announced the private placement of shares of its common stock to Chinese company ApolloBio Corporation to raise $35m in gross proceeds by the first half of this year.

Based in the US, Inovio develops vaccines for cancer and chronic infectious diseases.

Sanofi has agreed to sell its consumer healthcare portfolio to French pharmaceutical company Ipsen, subject to the European Commission’s approval.

The purchase consideration for the deal is €83m ($88.29m).